

Level 1, 3-5 George Street
Leichhardt
NSW 2040
Australia

+61 (0)2 9099 4750

investorqueries@atomodiagnostics.com

18th July 2023

Atomo Diagnostics Limited (ASX: AT1)

Not for release to US wire services or distribution in the United States

Dear Shareholder

As announced on 13 July 2023, Atomo Diagnostics Limited (ACN 142 925 684) (**Company**) has received firm commitments of \$1.25 million under a placement due to settle on 18 July 2023 (**Placement**) and plans to undertake an offer under a Share Purchase Plan (**SPP**) to raise up to an additional \$2.75 million.

On behalf of the Board, I am pleased to offer you the opportunity to subscribe for fully paid ordinary shares under the SPP.

The Company is offering eligible shareholders the opportunity to apply under the SPP for up to a maximum of A\$30,000 worth of fully paid ordinary shares in the Company (**New Shares**). Shareholders will be eligible to participate in the SPP if they have a registered address in Australia, New Zealand or the United Kingdom as at 7.00pm (AEST) on Wednesday, 12 July 2023 (**Eligible Shareholders**). Residents of New Zealand and the United Kingdom will also need to comply with certain requirements set out in the SPP Offer Booklet.

The exact pricing of the SPP is still to be determined, and will be set at the lower of:

- \$0.036 per New Share, being the price paid under the Placement; and
- 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP (5 Day VWAP), rounded to the nearest half cent, (the 'SPP Issue Price').

As the 5 Day VWAP will not be known until the Closing Date, the SPP Issue Price cannot be determined until the close of the SPP Offer.

The Company has applied to ASX for a waiver of Listing Rule 7.1, to permit the Company to issue New Shares under the SPP to be conducted in accordance with the ASIC Instrument, without shareholder approval, with the pricing to be determined as set out above, and on the condition that the number of New Shares issued under the SPP is not greater than 30% of the number of fully paid ordinary shares already on issue (**ASX Waiver**).

In the event that the ASX Waiver is not granted, the Company intends to seek Shareholder approval to issue the New Shares under the SPP, with such issue to be conditional on receipt of this shareholder approval.

SPP Offer Booklet

An offer document with the terms and conditions for the SPP offer was lodged with the ASX today (SPP **Offer Booklet**). A copy of the SPP Offer Booklet which contains information about how to apply under the Offer is available online at https://events.miraqle.com/at1-offer and on the Company's ASX Market Announcements Platform at https://www2.asx.com.au/markets/company/at1.

Atomo Diagnostics Limited ACN 142 925 684

You should carefully read the SPP Offer Booklet in full before making your investment decision, noting that you will be bound by the terms and conditions in the booklet if you choose to participate.

The Company intends to raise up to \$2.75 million under the SPP (before costs and subject to the Company's discretion to announce changes to this discretionary limit). Please refer to the SPP Offer Booklet for details as to the application of this discretionary cap and potential scale-back under the SPP.

The offer of New Shares under the SPP is made in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (ASIC Instrument). The ASIC Instrument grants relief from the requirement for Atomo to provide a prospectus in relation to the SPP. The ASIC Instrument limits the maximum amount that a shareholder is able to subscribe for to \$30,000 under the SPP or any similar arrangement in any consecutive 12 month period.

Important Information

The Board urges you to read these terms and conditions carefully and in their entirety before deciding whether to participate in the SPP.

If you are uncertain whether Shares are a suitable investment for you, you should consult your financial or other professional adviser. The Board recommends that you obtain your own financial advice in relation to the SPP and consider price movements of Shares in the Company prior to electing to participate in the SPP.

This letter is to notify you that the SPP Offer is now open and to provide you with instructions as to how to obtain a copy of the SPP Offer Booklet (which contains the Terms and Conditions of the SPP and your personalised Application Form

How to apply

Information with respect to applying for Shares under the SPP is outlined on your personalised Share Purchase Plan Application Form which you can download from the Company's offer website: https://events.miraqle.com/at1-offer. If you need to, you can also download a replacement personalised Application form from the Company's offer website.

Once you have your personalised Application Form, you can make a payment by BPAY®. To do this, you must use the unique identifier shown on the Application Form as the customer reference number when making payment. If you make your payment with BPAY® you do not need to return your Application Form.

You will not be able to withdraw or revoke your application or BPAY® payment once you have submitted it or made it or change the amount (in dollar terms) applied for.

BPAY® payments must be made from an Australian dollar account of an Australian financial institution.

For New Zealand and United Kingdom shareholders only, that are unable to pay by BPAY®, please contact the Share Registry on +61 1300 420 208 at any time from 8.30am to 5.00pm (AEST time) Monday to Friday during the Offer period for alternative electronic funds transfer payment arrangements.

You must ensure that your application and payment is received by 5.00pm (AEST) on Tuesday, 1 August 2023 (Closing Date). Application monies must be paid in Australian currency.

Participation in the SPP

The SPP is available to all Eligible Shareholders to apply for a minimum of \$1,000 and a maximum of A\$30,000 worth of Shares, in the increments set out in the Offer Document, at the Issue Price.

Applications for SPP Shares can only be made by Eligible Shareholders and your right to participate in the SPP is not transferable. Participation is optional and Eligible Shareholders may elect to do nothing. If you choose to do nothing, you will continue to hold the same number of Shares, however, your interest in the Company will be diluted.

Atomo Diagnostics Limited ACN 142 925 684

Key Dates

Event	Timing (Sydney time)
Record Date for the SPP	7.00pm Wednesday, 12 July 2023
Capital raising announced and trading halt lifted	Thursday, 13 July 2023
SPP Offer opens	Tuesday, 18 July 2023
Settlement of the Placement	Tuesday, 18 July 2023
Allotment of New Shares under the Placement	Wednesday, 19 July 2023
Commencement of trading of New Shares under Placement	Thursday, 20 July 2023
SPP closes	Tuesday, 1 August 2023
Announcement of results of SPP	By noon, Tuesday 8 August 2023
Allotment of New Shares under the SPP	Tuesday, 8 August 2023
Commencement of trading of New Shares under SPP	Wednesday, 9 August 2023

This timetable is indicative only and subject to change. The Company reserves the right to alter the above dates at any time, including amending the period for the SPP offer or accepting late applications, either generally or in particular cases, at its discretion and without notice to you, subject to the ASX Listing Rules, the Corporations Act 2001 (Cth) and any other applicable rules. The commencement of trading and quotation of new shares under the Placement and SPP offer is subject to ASX confirmation.

Enquiries

If you have any enquiries in relation to your Application Form or the SPP, please call Link Market Services Limited on 1300 420 208 (within Australia) or +61 1300 420 208 (outside Australia) between 8:30am to 5:30pm (AEST), Monday to Friday.

Yours faithfully

John Kelly Managing Director & CEO Atomo Diagnostics Limited

Disclaimer

The information in this letter does not constitute investment or financial product advice (nor tax, accounting or legal advice) nor any recommendation to acquire new shares in Atomo. It does not take into account any individual's investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate advice, including financial, legal, accounting and taxation advice appropriate to their jurisdiction. Atomo is not licensed to provide financial product advice in respect of the new shares.

Atomo Diagnostics Limited ACN 142 925 684